Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial symbols : Veru save search
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: -1.04%
H: 1.51%
C: -9.12%
fda treat clearance application trial
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
Published: 2023-09-26 (Crawled : 13:00) - globenewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 5.69%
H: 3.37%
C: -10.11%
fda sabizabulin respiratory trial agreement
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
Published: 2023-05-04 (Crawled : 12:00) - globenewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.06%
H: 0.29%
C: -0.7%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 0.0%
H: 2.36%
C: 0.0%
covid-19 fda sabizabulin treatment risk trial agreement
Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
Published: 2022-10-24 (Crawled : 14:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.01%
H: 2.19%
C: 1.07%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 0.63%
H: 0.6%
C: -3.2%
covid-19 treatment sabizabulin disease oxygen week presentation
Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
Published: 2022-07-06 (Crawled : 12:00) - globenewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.85%
H: 1.45%
C: 0.66%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 0.26%
H: 20.43%
C: 12.73%
covid-19 treatment sabizabulin trial results publication phase 3
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published: 2022-06-06 (Crawled : 11:00) - globenewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 10.2%
H: 0.0%
C: 0.0%
sabizabulin trial presentation positive cancer phase 2b prostate cancer
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 11:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 20.75%
H: 0.0%
C: 0.0%
covid-19 fda sabizabulin authorization positive phase 3 emergency use authorization
FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study
Published: 2022-05-02 (Crawled : 13:20) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 8.28%
H: 2.44%
C: -19.07%
covid-19 fda sabizabulin granted authorization positive phase 3 emergency use authorization
Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients
Published: 2022-04-25 (Crawled : 14:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -3.29%
H: 2.58%
C: 2.31%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 0.89%
H: 27.06%
C: 24.67%
covid-19 treatment sabizabulin presentation phase 2
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
Published: 2022-04-11 (Crawled : 12:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 37.7%
H: 143.24%
C: 105.01%
covid-19 drug sabizabulin phase 3
Veru/Lilly Aim to Fill Gap in Second-Line Metastatic Breast Cancer Therapy
Published: 2022-02-23 (Crawled : 14:00) - biospace.com/
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 2.12%
H: 1.54%
C: -3.88%
therapy cancer breast cancer metastatic breast cancer
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
Published: 2022-02-17 (Crawled : 14:30) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.88%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: -0.96%
H: 0.88%
C: -3.38%
prostate cancer symposium state phase 1b presentation asco phase 1 cancer sabizabulin phase 2b
Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 Trial
Published: 2022-02-01 (Crawled : 14:30) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.37%
H: 0.0%
C: 0.0%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 2.21%
H: 4.99%
C: 4.05%
verzenio trial collaboration phase 3
Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-01-31 (Crawled : 14:30) - biospace.com/
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 1.69%
H: 8.74%
C: 7.88%
covid-19 fast track designation treatment fda risk fast track respiratory covid grant syndros sabizabulin designation
Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer
Published: 2021-10-13 (Crawled : 13:00) - globenewswire.com
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 0.94%
H: 3.85%
C: 2.68%
test cancer phase 3 breast cancer trial enroll metastatic breast cancer
Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress
Published: 2021-09-20 (Crawled : 13:15) - biospace.com/
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: -4.25%
H: 3.62%
C: -1.17%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.14%
H: 1.4%
C: 0.04%
prostate cancer phase 1 positive cancer phase 1b sabizabulin phase 2b
Veru Announces Oral Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress
Published: 2021-09-09 (Crawled : 13:15) - biospace.com/
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: -1.31%
H: 5.75%
C: 3.73%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.33%
H: 0.06%
C: -1.44%
presentation prostate cancer phase 1 cancer phase 1b sabizabulin phase 2b
Veru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) in Metastatic Castration Resistant and Androgen Receptor Targeting Agent Resistant Prostate Cancer
Published: 2021-06-25 (Crawled : 13:00) - globenewswire.com
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 1.46%
H: 0.96%
C: -1.8%
prostate cancer cancer phase 3 trial enroll sabizabulin
Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer
Published: 2021-06-10 (Crawled : 13:00) - globenewswire.com
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: -0.33%
H: 0.89%
C: -1.0%
treatment phase 2 prostate cancer injection cancer trial hormone enroll
Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer
Published: 2020-12-14 (Crawled : 13:01) - globenewswire.com
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 55.31%
H: 9.73%
C: -1.77%
results breast cancer cancer positive endocrine trial trial results phase 2 metastatic breast cancer
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.